We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.23%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$402M
Cap. Flow
+$256M
Cap. Flow %
30.02%
Top 10 Hldgs %
54.49%
Holding
73
New
24
Increased
20
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.3M
2
AZN icon
AstraZeneca
AZN
+$41.9M
3
GSK icon
GSK
GSK
+$32.4M
4
UTHR icon
United Therapeutics
UTHR
+$28.6M
5
AMRN
Amarin Corp
AMRN
+$25.5M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.5M
2
OSUR icon
OraSure Technologies
OSUR
+$11.4M
3
HSKA
Heska Corp
HSKA
+$10.3M
4
LAB icon
Standard BioTools
LAB
+$9.68M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.33%
3 Financials 0.05%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$295M
$78M 9.15%
797,196
+264,523
+50% +$25.5M
UTHR icon
2
United Therapeutics
UTHR
$22.1B
$69.6M 8.17%
458,636
+217,732
+90% +$28.6M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$58.8M 6.89%
+376,200
New +$48.3M
TGTX icon
4
TG Therapeutics
TGTX
$8.26B
$44.9M 5.27%
863,851
-159,479
-16% -$5.39M
AZN icon
5
AstraZeneca
AZN
$252B
$42.6M 5%
426,216
+395,748
+1,299% +$41.9M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$38.8M 4.56%
530,976
-76,781
-13% -$5.71M
FATE icon
7
Fate Therapeutics
FATE
$291M
$36.3M 4.26%
399,499
-135,537
-25% -$8.42M
GSK icon
8
GSK
GSK
$102B
$35.2M 4.13%
757,265
+705,767
+1,370% +$32.4M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.3B
$31.2M 3.66%
187,043
+26,039
+16% +$4.31M
CTLT
10
DELISTED
CATALENT, INC.
CTLT
$29.1M 3.41%
279,503
+139,174
+99% +$13.5M
NVST icon
11
Envista
NVST
$4.36B
$29.1M 3.41%
+861,355
New +$25M
DHR icon
12
Danaher
DHR
$152B
$28.1M 3.29%
142,500
+107,126
+303% +$21.5M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$42.5B
$26.5M 3.11%
2,748,250
+353,895
+15% +$3.39M
AVTR icon
14
Avantor
AVTR
$9.86B
$25.9M 3.04%
+920,650
New +$23.7M
SRPT icon
15
Sarepta Therapeutics
SRPT
$2.2B
$23.6M 2.77%
138,644
+136,747
+7,209% +$20.3M
ELV icon
16
Elevance Health
ELV
$85.5B
$21.1M 2.48%
+65,771
New +$20.2M
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
$18.2M 2.13%
909,708
+44,467
+5% +$909K
QGEN icon
18
Qiagen
QGEN
$8.9B
$17.8M 2.09%
317,680
+159,744
+101% +$8.52M
ENSG icon
19
The Ensign Group
ENSG
$10.1B
$15.2M 1.78%
208,470
-110,393
-35% -$7.32M
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14.1M 1.65%
246,240
-156,193
-39% -$9.26M
GSK icon
21
CALL
GSK
GSK
$102B
$13M 1.52%
+282,080
New +$13M
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.3M 1.33%
356,235
+179,477
+102% +$4.72M
TARO
23
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$11.2M 1.31%
152,256
+10,367
+7% +$666K
HSKA
24
DELISTED
Heska Corp
HSKA
$11.1M 1.3%
76,166
-82,606
-52% -$10.3M
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
$10M 1.17%
+2,408,885
New +$9.51M
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Eversept Partners held 73 positions worth $852M, up 89% from $450M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Eversept Partners deployed $256M of net new capital in Q4 2020, opening 24 new positions and adding to 20 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $18.5M trimmed.

  • Eversept Partners's largest Q4 2020 buy was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.
  • Eversept Partners added most to AstraZeneca in Q4 2020, an estimated $41.9M increase.
  • Eversept Partners's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $18.5M.
  • Eversept Partners fully exited OraSure Technologies in Q4 2020, selling an estimated $11.4M.
  • Eversept Partners's ten largest holdings make up 54% of its $852M portfolio in Q4 2020.
  • Eversept Partners opened 24 new positions and closed 11 in Q4 2020.
  • Eversept Partners's portfolio value rose 89% quarter-over-quarter to $852M.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.